Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This phase 2 trial studies how well panitumumab-IRDye800 works in identifying head and neck cancer that has spread to the lymph nodes in patients with head and neck cancer. Panitumumab-IRDye800 may help surgeons to identify metastatic lymph nodes during surgical removal of the primary tumor and/or lymph nodes of the neck with equal or better accuracy than the current methods.

Official Title

A Phase II Study Evaluating Panitumumab-IRDye800 vs. Sentinel Node Biopsy and (Selective) Neck Dissection for Metastatic Lymph Node Identification in Patients With Head and Neck Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No


Fred M Baik, MD
Fred M Baik, MD
Head and neck surgeon, Surgical oncologist, Cutaneous oncology specialist
Assistant Professor of Otolaryngology - Head & Neck Surgery (OHNS)

Contact us to find out if this trial is right for you.


Grace Yi